Parse Biosciences

As we close out 2024 here at Parse Biosciences, we want to highlight some of the amazing milestones achieved this year alongside you, our research community! 🤝 Welcomed over 1,100 new researchers to the Parse customer community 🔬 Our customers profiled over 500,000,000 cells collectively 📖 95 new publications  🎖️ 14 single cell grants awarded 🔎 Trailmaker was used to analyze over 7,000 projects 🖥️ Generated 39 new Evercode datasets/resources 🔧 Added 30 service providers to our network 🌏 Welcomed 2 new global distributors 👋 Connected with you at 24 webinars and 74 conferences globally 🎉 Partied with 500 of you at Single Cell-ebration in Denver It's been an exciting year for the single cell community, and we can't wait to see what 2025 has in store. Thanks for being here with us! #parsewrapped #singlecell #researchcommunity

❄️🎁Wishing you happy holidays from all of us here at Parse Biosciences! #The12DaysOfParsemas #singlecell #HappyHolidays

📰 Parse is excited to add Admera Health to its growing network of certified service providers! “From the beginning, our mission at Parse Biosciences has been to make scalable single cell solutions as accessible as possible,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences. “Welcoming Admera Health into our network of trusted providers furthers this mission, empowering researchers to produce high-quality single cell data for any experiment with convenience and confidence.” Read the full release: https://parse.bio/3P6pgUi

📍Don't miss Ajay Sapre's talk today at 12:55 PT at Antibody Engineering & Therapeutics! Discover how our just-launched Evercode Mouse BCR is enabling new avenues in B cell characterization and accelerating antibody discovery research. Not at AET? Explore more here: https://parse.bio/3ZCs8gB

Attending Antibody Engineering & Therapeutics annual conference this week in San Diego? Join us for two amazing talks tomorrow, December 17th, and learn how Parse Biosciences and AbTherx are working together to improve antibody engineering and development with Evercode Mouse BCR! 👉Dan Rohrer, PhD presents Atlas™ Mice Provide a New and Differentiated Toolset for Rapid Generation of Developable Human Therapeutic Antibodies 👉Ajay Sapre presents Deep Mining of Antibody Repertoires with Single Cell B Cell Sequencing Tools from Parse Biosciences #AntibodyEng #SingleCell #MouseBCR #BCR #Evercode #CellSequencing

💻 ✨ Huge thanks to everyone who tuned into yesterday's webinar! Special shoutout to our brilliant speaker, Dr. Robert Albero Gallego, who delivered an incredible presentation breaking down the comparative analysis between Parse and other single-cell technologies. The full presentation is now available to view on-demand: https://parse.bio/49DK13h The proof is in the data!🔬Ready to try Evercode technology for yourself? Get in touch with our team today to get started. #Evercode #SingleCell #Research #DitchDroplet

📰🐭We're thrilled to announce the launch of our Evercode Mouse BCR! These new kits capture full-length BCR sequences from mouse samples, enhancing their utility for immunological studies. "With the expansion of Evercode BCR to support studies in mice, researchers can comprehensively characterize the immunological responses in disease-specific mouse models and accelerate their antibody discovery efforts," said Charles Roco, Chief Technology Officer and co-founder of Parse Biosciences. Read the full press release: https://parse.bio/4gqTwVs #Evercode #MouseBCR #BCR #Immunology #DitchDroplet #SingleCell

🔬Breaking Down Single Cell Technologies: Parse vs. Alternative Methods Join us for an in-depth comparative analysis where Dr. Robert Albero Gallego reveals critical insights on: - QC strengths and biological implications - Detection capabilities for low-expression genes - Key differentiators between Evercode and other technologies 📆 December 12th (tomorrow!) ⏰ 7:00 AM PST 📍 Virtual Webinar Register now: https://parse.bio/3BAfMgN #SingleCell #Research #DitchDroplet

🚨 🧠 Scientists combined snRNA-seq with spatial transcriptomics to map human and mouse brain regions, uncovering localized vulnerabilities possibly affecting cognition and a disrupted glial inflammatory program driving disease. Read the publication: https://parse.bio/4g8YSVD #AlzheimersResearch #SpatialTranscriptomics #ParseBiosciences #Neuroscience #Genomics #InnovationInScience #TranslationalResearch

AI Drug Discovery Dataset Tops 100M Cells in Vevo, Parse Partnership A collaboration between Parse Biosciences’ GigaLab and Vevo Therapeutics has generated what they say is the largest single-cell dataset to date. The Tahoe-100M dataset comprises 100 million cells and covers 60,000 conditions, 1,200 drug treatments, and 50 tumor models. Vevo plans to use the dataset to advance its artificial intelligence-based drug discovery efforts.  The partnership leveraged single-cell RNA sequencing capabilities from Parse as well as high-throughput sequencing functionality from Ultima Genomics. The project was completed in about a month. https://hubs.li/Q02-JZkC0